- The management has raised and narrowed its FY26 adjusted earnings per share guidance range to $38.05 to $38.55 from the previous range of $37.10 to $37.90
- It has increased its long-term adjusted earnings per share growth target to 13% to 16% from the prior range of 12% to 14%
- McKesson continues to strengthen its portfolio of differentiated assets and capabilities, advancing health outcomes for all
- The company said it is well-positioned to capture long-term growth opportunities through disciplined execution of its strategic priorities and sustained operational momentum
- The long-term adjusted operating profit growth forecast for the North American Pharmaceutical business segment is 5% to 8%
- Oncology & Multispecialty operating profit, on an adjusted basis, is expected to grow 13% to 16% in the long term
- The company expects long-term adjusted operating profit for the Prescription Technology Solutions division to grow 10% to 13%
Market News
McKesson Corporation (MCK) raises FY26 earnings guidance
McKesson Corporation (NYSE: MCK), a diversified healthcare service company that operates in partnership with biopharma companies and care providers, has published its updated long-term financial targets. The management has raised and narrowed its FY26 adjusted earnings per share guidance range to $38.05 to $38.55 from the previous range of $37.10 to $37.90 It has increased […]
NYSE
$MCK · Earnings
“McKesson Corporation (NYSE: MCK), a diversified healthcare service company that operates in partnership with biopharma companies and care providers, has published its updated long-term financial targets. The management has raised and narrowed its FY26 adjusted earnings per share guidance range to $38.05 to $38.55 from the previous range of $37.10 to $37.90 It has increased […]
· September 24, 2025
McKesson Corporation (NYSE: MCK), a diversified healthcare service company that operates in partnership with biopharma companies and care providers, has published its updated long-term financial targets.
ADVERTISEMENT